Pediatric Drugs: the Worldwide Market, 3rd Edition Although much of medicine is focused on the increased aging of the population, children still represent the bulk the dependent population worldwide. Important regulatory factors are also at work in the pediatric pharmaceutical market. The recognition of the rights of children to have access to safe and effective drugs and the needs of healthcare providers to have access to age-appropriate drug information continues to have a major effect on all areas of pediatric pharmaceuticals including pediatric biomedical research. Pediatric Drugs, the Worldwide Market is the completely updated edition of Kalorama Information’s 2005 study on prescription pediatric drugs focuses on the following treatment segments:
- Allergy and Respiratory Drugs
- Anti-Infectives
- Cancer Therapies
- Cardiovascular Drugs
- Central Nervous System Drugs
- Gastrointestinal Drugs
- Hormone Drugs
- Other Pediatric Drugs
The 500-page report includes global statistical information for conditions and diseases affecting pediatric populations, including detailed discussions and over 180 exhibits. Each segment provides an ,
- Overview,
- Descriptions of products on the market,
- Market estimates and forecasts (U.S. and non-U.S.), and
- Competitive analysis of leading providers including market share
In addition, the report includes extensive tables of products in research and development and approved prescription drugs for which additional pediatric information may produce health benefits in the pediatric population. There are also in-depth discussions of current issues and trends affecting the industry and what trends may arise in the future. The research conducted by Kalorama Information included comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Person-to-person and telephone interviews were the primary method of gathering information. Interviews with over 100 key industry officials, consultants, health care providers, and government personnel were complied to form the primary basis of information-specifically revenue and market share data-presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives. All market data pertain to the world market at the manufacturers’ level. The base year for data was 2006. Historical data are provided for 2004 and 2005 with forecast data provided for 2007 through 2011. Compound annual growth rates (CAGRs) are provided for the 2004-2006, 2006-2011, and 2004-2011 periods for each industry segment covered.
Pages: 490 Format PDF Pub Date: 01/12/2007 Table of Contents Sample Page (PDF) Price: $3,995.00 / GBP1,997.50
|